tbuckley/cabot-search huggingface dataset:
Prediction of late distant recurrence (DR) using the Prosigna (PAM50) test in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal women diagnosed with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET).
Authors: Anne-Vibeke Lænkholm, Maj-Britt Jensen, Jens Ole Eriksen, Torben Kibøll, Birgitte Bruun Rasmussen, Ann S. Knoop, Sean Ferree, Taryn Haffner, Carl Schaper, Bent Ejlertsen
Journal: Journal of Clinical Oncology (2015)

544 Background: Accurate assessment of the risk of late DR (5-10 yr after surgery) may be used to tailor the duration of ET for patients with HR+ EBC. The Prosigna (PAM50) risk of recurrence (ROR) score was shown to predict late DR for EBC patients treated with 5yr of ET in two randomized clinical trials. Here we assess the ability of PAM50 to predict late DR in a comprehensive nationwide cohort from Denmark consisting of postmenopausal women diagnosed with HR+ EBC allocated to 5yr of ET alone. Methods: Using the population based DBCG database FFPE primary tumor blocks and follow-up data were collected from all HR+ EBC patients diagnosed from 2000-2003 who by nationwide guidelines were allocated to 5yr of ET alone (N = 2749). The PAM50 test was run on the NanoString nCounter Analysis System. Multivariate analyses tested the ability of PAM50 to predict late DR. Patients were categorized as Low, Intermediate, or High risk based upon prespecified ROR cutoffs varied by number of positive nodes. Results: From 2722 included patients, 2164 were disease free at 5yr and analyzed for risk of late DR. Median follow-up was 4.58 years from completion of ET. High risk patients (N = 870) had a late DR risk of 10.2% [95%CI: 8.0-12.7], compared to 6.1% [4.2–8.6] for Intermediate (N = 650) and 2.4% [1.3–4.1] for Low risk patients (N = 644). When ROR was added to a multivariable model including standard clinical and pathological variables it improved the prediction of late DR (likelihood ratio: p < 0.0001; HR for a 20-point change = 1.5 [1.2–1.9]). Luminal B (N = 733, late DR risk = 10.3% [7.8–13.1]) and Her2-enriched patients (N = 132, late DR risk = 8.8% [4.4–15.0]) had a significantly worse outcome than Luminal A (N = 1281, late DR risk = 4.5% [3.3–5.9]), p < 0.0001 for LumB and = 0.034 for Her2e. Conclusions: We have confirmed the ability of Prosigna (PAM50) to predict late DR for HR+ EBC patients regardless of nodal status in a real world cohort devoid of physician selection bias. PAM50 can reliably be utilized to identify patients who need, or most importantly may be safely spared, extended ET beyond 5yr.
Problems of Oral Contraceptives Given during Pregnancy
Journal: New England Journal of Medicine (1975)

In the recent article by Janerich et al. (Janerich D.T. Piper J.M. and Glebatis D.M.: Oral contraceptives and congenital limb-reduction defects.  New England Journal of Medicine 291: 697 1974) as well as in the editorial in the same issue a conclusion is drawn that it would be prudent to discontinue the use of the hormone-withdrawal type of pregnancy test because of a possible risk  of a limb-defective child.  The data on which the authors base this condemnation of an exceedingly useful clinical test seem to bear close scrutiny.  Among the 10 mothers in this report given oral contraceptives when pregnant there was but one who took the pills only for the 4 or 5 days of a test dosage.  3 were given the pills as a supportive measure and 6 continued their oral steroids into an undiagnosed breakthrough pregnancy.  5 others received steroid injections (unspecified).  In this report there were 190 limb-reduction cases among the 942925 births covered in the study period 10 of which excluding the injection cases might casually be related to oral contraceptives - an incidence of slightly over 1/100000.  However in only one of these was the medication prescribed for the few days of the oral test - an incidence of approximately one in a million.  The authors may be commended for pointing out that sex hormones should not be given as a supportive measure for pregnancy.  They have introduced the still unexplained possibility of some underlying maternal reproductive problem and a sex-specific effect of these sex steroids.  But the evidence calling for abandoning the use of oral contraceptives for only 4 or 5 days as a pregnancy test seems fragile indeed.(FULL TEXT)
Abstract 12722: CABG Versus PCI in Patients with Diabetes: A Metaanalysis of Randomized Controlled Trials in the Era of Stents
Authors: Subodh Verma, Bobby Yanagawa, Muhammad Ahsan, David H Fitchett, Milan Gupta, Shantanu Singh, Nandini Gupta, David A Latter, Marc Ruel, Michael E Farkouh, Jan O Friedrich
Journal: Circulation (2013)

Background: Despite results of recent trials, controversy still exists as to whether coronary artery bypass graft (CABG) surgery is superior to percutaneous coronary intervention (PCI) in diabetic ...
Abstract 402: Pasireotide reduces chemoresistance in pancreatic tumor cells by inhibiting the synthesis and secretion of growth factors from tumor associated fibroblasts
Authors: Camille Duluc, Siham Moatassim, Mounira Chalabi, Aurélie Perraud, Yvan Martineau, Florence Breibach, Marie-Bernadette Delisle, Muriel Mathonnet, Herbert A. Schmid, Stéphane Pyronnet, Corinne Bousquet
Journal: Cancer Research (2015)

Abstract Pancreatic ductal adenocarcinoma (PDAC) is extremely rich in stroma. By secreting tremendous amounts of soluble and un-soluble proteins, stromal cancer-associated fibroblasts (CAFs) can induce tumor chemoresistance by activating survival signals in cancer cells and preventing drug delivery through increased fibrosis. Our results demonstrate that chemoresistance triggered by the CAF secretome is strongly reduced upon inhibition of CAF protein synthesis. This is achieved by impinging upon the PI3K/mTOR/4E-BP1 pathway that we found highly activated in primary cultures of alpha-SMA-positive CAFs isolated from human PDAC. CAFs, but not normal pancreatic fibroblasts, express primarily the sstr1 somatostatin receptor subtype whose activation by the somatostatin analogue SOM230 (Pasireotide) strongly inhibits the PI3K/mTOR/4E-BP1 pathway and the resulting synthesis of secreted proteins including IL-6 and collagen-I. As a consequence, the growth and chemoresistance of pancreatic tumors provided by co-injection of CAFs in nude mice are overcome when chemotherapy (such as gemcitabine) is combined to pasireotide treatment. While gemcitabine or pasireotide alone have marginal effects, the combined treatment markedly decreases fibrosis and strongly enhances cancer cell apoptosis due to increased cell sensitivity to gemcitabine. We propose that selective inhibition of CAF protein synthesis and secretion with sstr1-directed pharmacological compounds represents an anti-stromal targeted therapy with a promising potential in chemosensitization. Citation Format: Camille Duluc, Siham Moatassim, Mounira Chalabi, Aurélie Perraud, Yvan Martineau, Florence Breibach, Marie-Bernadette Delisle, Muriel Mathonnet, Herbert A. Schmid, Stéphane Pyronnet, Corinne Bousquet. Pasireotide reduces chemoresistance in pancreatic tumor cells by inhibiting the synthesis and secretion of growth factors from tumor associated fibroblasts. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 402. doi:10.1158/1538-7445.AM2015-402
Oral health screening should be routine in professional football: a call to action for sports and exercise medicine (SEM) clinicians
Authors: Ian Needleman, Paul Ashley, Richard Weiler, Steve McNally
Journal: British Journal of Sports Medicine (2015)

In the January 2016 issue of BJSM , we showed that professional footballers in the UK have poor oral health and this is associated with negative self-reported impacts on training, performance and well-being.1 Since more than 90% of each senior squad participated in the study, we can be confident that the results represent a true picture. These findings are also consistent with data we collected during the London 2012 Olympic Games and a recent systematic review.2 The emerging picture is of poor oral health in elite sport with important self-reported impacts on self-reported performance. In this call to action for oral health screening in professional football we: (1) place players’ oral health alongside UK norms, (2) make the case that footballers are at high risk of poor oral health and (3) set out the case for screening and how this could lead to improved oral health in professional football.

Oral …
Bariatric surgery versus non-surgical treatment for obesity
Authors: Viktoria L Gloy, Matthias Briel, Deepak L Bhatt, Sangeeta R Kashyap, Philip R Schauer, Geltrude Mingrone, Heiner C Bucher, Alain J Nordmann
Journal: British Journal of Sports Medicine (2016)

STUDY QUESTION What are the summary effects of bariatric surgery compared with non-surgical treatment for obesity on body weight loss, comorbidities, adverse events, and quality of life? SUMMARY ANSWER Bariatric surgery is more effective in inducing body weight loss and remission of type 2 diabetes and metabolic syndrome after a maximal follow-up of 2 years, no cardiovascular events or deaths were reported after bariatric surgery, and the most common adverse events after bariatric surgery were iron deficiency anaemia and reoperations.
Recent Advances in Respiratory Tuberculosis
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficiency of different strategies of asthma control achievement in real clinical practice
Authors: Evgeny Kulikov, Ludmila Ogorodova, Ivan Deev
Journal: European Respiratory Journal (2011)

Introduction: Epidemiological studies registered the asthma control prevalence in the population at 5% on average but controlled studies showed that control achievement is possible in more than 70% of patients. There is no clear what part of asthma patients can have controlled asthma and which therapy regimen will be optimal in real clinical practice.

Aim: To compare the efficiency of strategies of control achievement in patients with persistent asthma in real clinical practice.

Methods: Multicenter prospective 24-week observation study was conducted in 19 centers in Russia. The following data were collected: ACT score, FEV1, therapy changes, number of emergency visits. The investigator was only to record the changes of therapy prescribed by the physician of patient. Patients were aposterior stratified into three groups: A – step-up regime of combined therapy (salmeterol/fluticasone propionate), B – stable regime, C – step-down regime.

Result: At the end of the observation disease control criteria in group A was achieved in 73,3% of cases, 69,4% in group B, and 58,5% in group C. The positive FEV1 dynamics was registered in the group A and group B – 6.4±1.5% and 5.0±1.5%, respectively. There was the negative dynamics of the FEV1 in group C (-8.2±2.8). Using of A and B strategies increased the probability of the full control achievement 3 times in comparison with the Group C (OR 3.27; 95%CI 1.48-7.35 and OR 3.36; 95%CI 1.53-7.54, respectively). Highest emergency visits frequency was registered in the group C (18,2%; Group A - 2.6% and B - 5.8% (p<0.001 vs A; p=0.01 vs B).

Conclusion: In the real clinical practice the use of combination therapy at step-up dose or in stable dose are optimal.
Incidence of treatment-related toxicities in head and neck cancer Medicare patients
Authors: K. K. McLaurin, G. Ciesla, P. A. Kamimoto, I. Chico, M. Apostolaros, S. Leader
Journal: Journal of Clinical Oncology (2005)

8042 Background Radio- and chemotherapy to the head and neck region cause acute side effects and chronic sequela; however, the incidence of these toxicities is not well known. Surveillance, Epidemiology and End Results registry data linked to Medicare claims (SEER-Medicare) provide a population-based assessment of treatment patterns and outcomes among patients with head and neck cancer. Methods Head and neck cancer patients diagnosed in 1999 were retrospectively identified in the SEER-Medicare data and followed 1 year post diagnosis. Patients were age or disability eligible, continuously enrolled in Parts A and B and not in an HMO. HCPCs and ICD-9 procedure codes identified radio-/chemotherapy (RC), radiotherapy (R), or chemotherapy (C). ICD-9 diagnosis codes were assigned to toxicities and identified anywhere on the claims record. The diagnosis was considered treatment-related if it occurred on or after the date of first treatment but not in the prior year. Patients with a prior toxicity diagnosis were not included in the denominator for toxicity rate calculations. Results 860 patients were treated with R (68%), RC (27%) or C (5%). Regardless of treatment type, most patients were male (65%), white (82%) and over age 65 (91%). One year survival by treatment type was R (78%), RC (73%) and C (53%). Historic stage at time of diagnosis was reported as local (R=41%, RC=22%), regional (R=44%, RC=61%) and distant (R=6.5%, RC=12.4%). Oral complications such as dysphagia, mucositis and xerostomia were among the most common toxicities (see table). Conclusions Patients diagnosed with distant (metastatic) cancer received more aggressive treatment and experienced higher toxicity incidence and hospitalization rates. Appropriate measures should be taken to minimize toxicities and thereby decrease treatment interruption and increase patient quality of life. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration MedImmune MedImmune
Outcome of well differentiated thyroid cancer: Single institution results
Authors: S. Aksoy, H. Abali, S. Kiliçkap, Ö. Yavas, B. Oyan, E. T. Elkiran, T. Aras, Ö. Ugurlu, N. Güler, G. Tekuzman
Journal: Journal of Clinical Oncology (2004)

5615 Background: The primary goal of this study is to present the single institution experience with emphasis on clinical, pathological and therapeutic measures on the outcome of differentiated thyroid cancer (DTC). Methods: Cases of DTC were retrospectively analyzed for the period of 1986 to 2003 the Medical Oncology Department of the Hacettepe Medical Faculty. Results: A total of 118 patients with papillary (PC) and follicular thyroid cancer (FC) were included in this retrospective study. The median age was 37 years in PC and 49 years in the FC patients. Histologically; 93 (68 female and 25 male) (78.8%) patients have PC and 25 (20 female, 5 male) (21.2%) FC. Nearly half had a near total or total thyroidectomy and other half lobectomy or a partial thyroidectomy. Fifty-four (%45.8) patients underwent to additional surgery due to insufficient primary surgery. There was no disease free survival (DFS) difference between these groups. There was no difference in DFS among males and females, in the subgroups of <45 and >45 year age groups and PC and FC subtypes. The median tumor size was 1.8 cm for papillary, 2.2 cm for follicular and 2.0 cm in overall. The tumor size ≥2 cm associated with worse DFS (p = 0.028). Extrathyroidal extension, multicentricity, vascular invasion, lymph node involvement of tumor did not affect the DFS. Eight patients developed distant metastasis; most frequent sites were lung and bone. The median period of time to develop metastasis was 50.0 months (16–95 months). Ninety-eight (83.1%) patients received ablative I-131 with the median dose of 132.5 mCi and 20 (16.9%) patients did not. Twenty-nine patients (24.6%) required additional treatments, which the median dose was 150 mCi. There was no difference in DFS between the patients treated with and without I-131 therapy. Two patients died from disease till the time of analysis. Median follow up period is 57.0 months (1 to 200). DFS rate for five years was 93.2%. Over all survival rate for five years was 98.3%. Conclusions: In our study, tumor size is the only prognostic factor for DFS. The extent of surgery and dose of I 131 therapy, in this study did not affect long term disease free survival. I 131 therapy may be beneficial in selected patients only. No significant financial relationships to disclose.
Phase II study of capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal carcinoma
Authors: R. Xu none, Y. Li, H. Luo, F. Wang
Journal: Journal of Clinical Oncology (2009)

e15125 Background: The purpose of this study was to evaluate the safety and efficacy of the capecitabine-oxaliplatine combination (XELOX) in Chinese patients with metastatic colorectal carcinoma (mCRC). Furthermore, we aimed to explore whether a maintenance therapy with oral capecitabine in patients responding to XELOX is able to maintain the response and improve the duration of disease control (DDC). Methods: Patients with mCRC were treated with a 3-weekly regimen of oxaliplatin at a dose of 130 mg/m 2 intravenously on Day 1 plus capecitabine 1000 mg/m 2 orally twice daily from Days 2 to 15. Patients who did not progress after finished the XELOX therapy were choice to stop or receive oral capecitabine until disease progression or unacceptable toxicity. Results: 124 patients received a total of 637 cycles (median, 6) of treatment. Responses rate was 49.1%. Median overall and median progression-free survival was 20.0 months and 8.0 months, respectively. Main grade 3–4 drug-related toxicities included neutrapenia (5.6%), nausea/vomiting (4%), thrombocytopenia (2.4%), and hand-foot syndrome (2.4%). 23 of 101 patients responding to XELOX received oral capecitabine as maintenance therapy.The median DDC was 8 months for patients in the group of not using maintenance therapy, versus 12 months in the group of using capecitabine as maintenance therapy. Conclusions: XELOX is a highly effective first-line treatment for mCRC and provides a more convenient regimen, likely to be preferred by both patients and healthcare providers. Furthermore, these results support the feasibility of maintaining good response and improving DDC with oral Capecitabine after combination chemotherapy in mCRC. No significant financial relationships to disclose.
Calvert's formula and high-dose carboplatin.
Authors: B Uziely, S C Formenti, K Watkins, A Mazumder, F M Muggia
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.8.1740 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8040687 Calvert's formula and high-dose carboplatin. B UzielyxB UzielySearch for articles by this author , S C FormentixS C FormentiSearch for articles by this author , K WatkinsxK WatkinsSearch for articles by this author , A MazumderxA MazumderSearch for articles by this author , F M MuggiaxF M MuggiaSearch for articles by this author https://doi.org/10.1200/JCO.1994.12.8.1740 PDF "Calvert's formula and high-dose carboplatin.." Journal of Clinical Oncology, 12(8), pp. 1740–1741© 1994 by American Society of Clinical Oncology
Outbreak of lymphogranuloma venereum among men who have sex with men in Barcelona 2007/08 – an opportunity to debate sexual health at the EuroGames 2008
Authors: M Vall Mayans, E Caballero, P Garcia de Olalla, P Armengol, MG Codina, MJ Barberà, B Sanz, A Andreu, J Caylà
Journal: Eurosurveillance (2008)

Lymphogranuloma venereum (LGV) is a systemic sexually transmitted infection (STI) caused by Chlamydia trachomatis (L serovars L1, L2 or L3). Since 2003, several outbreaks of rectal LGV affecting men who have sex with men (MSM) have occurred in western Europe [1]. The first case in Spain was confirmed in Barcelona in 2005 [2], but no further cases have been detected in this city since until September 2007. We briefly summarise the characteristics of the LGV cases diagnosed at the outpatient STI clinic in Barcelona between September 2007 and April 2008.
Use of microRNAs to distinguish small from non-small lung cancer
Authors: Y. Spector, E. Meiri, A. Faerman, M. Ben David, M. Zepeniuk, M. Ezagouri, D. Cohen, S. Rosenwald, M. Perelman, I. Barshack
Journal: Journal of Clinical Oncology (2009)

e22061 Background: Lung tumors are divided to two main classes: non-small cell lung cancer (NSCLC) that accounts for ∼80–85% of all lung primary tumors, and tumors from neuroendocrine origin - mainly small cell lung carcinoma and lung carcinoid. The classification of lung tumors can present a diagnostic challenge. New markers for different subtypes may aid in diagnosing difficult cases, can improve the accuracy of classification and could be important for selecting proper treatment. Here we studied the utility of microRNA as biomarkers for this differential diagnosis. MicroRNAs, a family of short non-coding regulatory RNAs, are highly tissue-specific and are well preserved in routinely prepared formalin-fixed, paraffin-embedded (FFPE) specimens, making them promising candidates as biomarkers for tissue and tumor classification. Methods: We used proprietary protocols for extracting high-quality RNA from FFPE samples. We used microRNA microarrays to profile more than a hundred samples from different histological subtypes of lung cancer including small cell, lung carcinoid and various types of NSCLC. Differential microRNA expression was verified using a microRNA qRT- PCR platform. Results: We found that several microRNAs are significantly differentially expressed between different subtypes of lung cancers. Specifically, using combinations of few microRNAs, we were able to accurately differentiate between neuroendocrine and NSCLC. Small cell and carcinoid tumors can be further distinguished using the signals of additional microRNAs, with very high sensitivity and specificity. Conclusions: Our results underscore the potential of microRNA expression for classification of tumor subtypes. We found that combinations of small numbers of microRNAs can successfully aid in the differential diagnosis of lung tumors, and provide a basis for the development of simple and reliable assays for clinical oncology. [Table: see text]